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undertaken to rationalize prescribing in an emergency de-
partment (ED). 
METHODS: The annual census of our ED is 50,000 pa-
tients, 40% of whom receive prescription drugs. Prescrip-
tions written by a total of 57 physicians were collected
during 5 days before (P1) a 45-day intervention, then 5
days immediately after (P2) and 12 days, 3 years later
(P3). The intervention was an educational program with
emphasis on contraindications and adverse effects. Con-
forming indications were either established (E) (mainly
rheumatological) or admitted (A) but controversial (trauma,
ENT). For the latter, NSAIDs may be withheld. Between
P1 and P2 all E&A indications were shown. Between P2
and P3, only the E indications were available. Prescribing
errors were the main endpoint. 
RESULTS: NSAIDs were prescribed for 37/434 patients
(8.5%), 42/414 (10%), and 12/583 (2%), respectively
(p  0.0001). Between P1 and P2, prescribing errors de-
creased from 19% to 14% (p  0.76). In P3, 1 was
found. Between P1 and P3, conforming prescriptions in-
creased from 81% to 92% (p  0.66): NSAIDs decreased
for trauma (50% to 8%; p  0.02) and increased for
rheumatology (19% to 42%; p  0.14). Duration of
treatment decreased from 8.0–4.0 days to 6.0–3.0 days
(p  0.07). 
CONCLUSIONS: Overall NSAIDs as well as incorrect
prescribing decreased after an intervention. However, 1)
“Soft indications” stimulated prescribing; 2) Its curbing
was obtained by a limited list between P2 and P3. This
approach may be applied to other controversial drugs.
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Significant opportunities for patient safety are potentially
achievable with the introduction of the cycloxygenase-2
(COX-2) inhibitors. Unfortunately, constrained health-
care budgets may limit their use. 
OBJECTIVE: To describe a NSAID therapeutic portfolio
that maximizes medical benefits, but does not increase
existing healthcare costs. 
METHODS: A meta-heuristic assisted optimization of a
typical HMO’s NSAID portfolio after the introduction of
celecoxib 200 mg QD was conducted using linear pro-
gramming techniques. Current NSAID  antiulcerant us-
age and the cost of managing NSAID related gastropathy
was derived from a large HMO. Background antiulcerant
usage was established from an equivalent non-NSAID ex-
posed arthritis population. The probabilities of NSAID
related gastrointestinal events were derived from clinical
trials and the literature. Decreased hospitalized gas-
trointestinal events without increasing the overall health
budget were defined as the optimization criteria. Antiul-
cerant usage was not allowed to decrease below the back-
ground rate.
RESULTS: Assuming an average risk of NSAID-induced
GI toxicity and 150 days/year of therapy, the average
cost/patient/year for NSAID therapy and related adverse
events would be $366. If celecoxib is introduced into the
healthcare system, 74% of patients could be switched to
the agent without increasing the overall budget, provided
that the remaining patients were distributed as follows:
13% generic ibuprofen; 9% generic NSAID  H2 block-
ers or prostaglandins; and 4% generic NSAID  PPI.
During a 1-year period, this distribution of agents would
result in 29 fewer physician visits and two less hospital-
ization per 1000 patients. 
CONCLUSIONS: These results indicate that by optimiz-
ing the distribution of NSAIDs utilized within a HMO, a
significant number of osteoarthritic patients can receive
safer COX-2 specific compounds such as celecoxib with-
out increasing the total budget.
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OBJECTIVE: To provide a clinically meaningful inter-
pretation of improvements in WOMAC scores among
OA patients. 
METHODS: Data were obtained from three 12-week ran-
domized clinical trials among 3369 OA flare patients. The
Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC), PtGA & PhGA were administered at
baseline and week 12. WOMAC is a 24-item instrument
that contains three domains: pain, stiffness, and physical
functioning and a summary score. PtGA & PhGA were
measured on the following 5-point scale: very good, good,
fair, poor, or very poor. Change scores were computed by
subtracting patient’s baseline from week 12 follow-up
scores. Responsiveness was estimated as the mean change
score corresponding to each level of PtGA or PhGA im-
provement. 
RESULTS: At week 12, the number of patients experi-
encing improvements in PtGA and PhGA were: 1108 and
1158 for one-level, 708 and 745 for two-levels, and 368
and 311 for three or more levels. The average improve-
ment of WOMAC domain and total scores among pa-
tients experiencing one, two, or three or more levels of
PtGA improvement were 2.3, 4.4, 6.5 for pain, 1.0, 1.7,
2.5 for stiffness, 7.3, 13.9, 20.4 for physical functioning,
and 10.1, 18.7, 27.4 for total WOMAC score. A similar
responsiveness was found between average WOMAC
scores and PhGA improvement, which were 2.3, 4.4, 6.6
for pain, 1.0, 1.7, 2.5 for stiffness, 7.5, 13.6, 21.0 for
physical-functioning, and 10.3, 18.6, 27.9 for total
WOMAC score. 
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CONCLUSION: Using change scores responding to a
one-level improvement of PtGA or PhGA or using the av-
erage difference of change between any two levels im-
provement of PtGA or PhGA, the clinically meaningful
improvement for WOMAC pain, stiffness, physical func-
tioning, and total WOMAC scores were approximately
2, 1, 7, and 10, respectively.
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HRQoL measures are becoming important for evaluating
the effects of arthritis treatments. Interpreting changes in
HRQoL scores, however, has not been fully evaluated. 
OBJECTIVE: To determine the clinically meaningful im-
provement of HRQoL as measured by the SF-36 among
OA patients. 
METHODS: Data were obtained from three 12-week ran-
domized clinical trials among 3369 OA flare patients. The
SF-36 and Patient Global Assessment (PtGA) were admin-
istered to patients at baseline and week 12. PtGA was
measured on the following 1- to 5-point scale: very good,
good, fair, poor, or very poor. Change scores were com-
puted by subtracting patient’s baseline from week 12 fol-
low-up scores. Clinically meaningful improvement was es-
timated as the mean change score corresponding to a one-
level improvement in PtGA. A similar interpretation of
clinically meaningful changes was also performed using
physician-global assessment, pain, and functional-status. 
RESULTS: At week 12, the following patients experi-
enced improvements in their PtGA rating: one-level
(1158), two-levels (745), three or more levels (311),
which corresponded to standardized physical and mental
component scores (PCS & MCS) improvements of: one-
level (3.8 and 1.4), two-levels (8.3 and 2.7), and three or
more levels (10.4 and 4.2), respectively. The clinically
meaningful improvement based on PtGA among OA pa-
tients were approximately 3.8 and 1.4 for PCS and MCS,
respectively. The clinically meaningful changes for eight
SF-36 domains were 7.2 for physical function, 13.1 for
role physical, 11.6 for bodily pain, 2.1 for general health,
5.6 for vitality, 6.2 for social function, 7.7 for role emo-
tion, 2.7 for mental health. 
CONCLUSION: Clinically meaningful improvement var-
ies between SF-36 domains and summary scores among
OA patients. These results provide guidance in interpret-
ing HRQoL results and planning clinical trials.
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Given the widespread use of NSAIDs and its association
with gastric injury, the patterns and costs of gastric toxic-
ity are of interest. 
OBJECTIVE: The goal of this study was to describe the
prevalence of concomitant antiulcer medication with
NSAIDs. 
METHODS: We identified patients diagnosed with os-
teoarthritis (OA) (ICD-9 codes: 715, 721.0, 721.3,
721.9), rheumatoid arthritis (RA) (ICD-9 codes: 714.0,
714.1, 714.2, 714.9) or both (OA/RA) between 1992
and 1997 using a managed care claims database. Study
participants had at least 12 months of continuous health
coverage (including drug benefits). We examined initial
NSAID choice and the prevalence of concomitant gas-
trointestinal (GI) drug use (H2 antagonists [H2], proton
pump inhibitors [PPI], prostaglandins [PS]) during the
study period. 
RESULTS: Among NSAID users (n  40,350), ibuprofen
(28.6%) and naproxen (18.2%) were most likely to be
prescribed initially. Antiulcer medication use was more
prevalent in patients receiving NSAID therapy, appeared
to increase with age and vary by diagnosis: rates varied
from 19.1% (OA), 19.6% (RA), 34.3% (OA/RA) in pa-
tients aged 18–39 to 29.2%, 32.3%, and 40.0% in pa-
tients aged 70–79. Fifteen percent of patients had a con-
comitant GI prescription added to their therapy within
60 days after the first NSAID prescription. Most of the
anti-ulcerant use was H2 (76.9%), although PPI use
(10.7%) and PS use (12.4%) increased in latter years. 
CONCLUSIONS: We found that the prevalence of GI
therapy varied by age and diagnosis and that concomi-
tant GI medication use began soon after the initiation of
NSAID therapy.
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The West Virginia Medicaid’s (WVM) prior authoriza-
tion (PA) policy for NSAIDs is expected to produce sav-
ings to the WVM for two reasons: 1) NSAIDs are among
the most frequently utilized drugs in WVM, and 2) while
prices for NSAIDs vary substantially, most of the pre-
scribed NSAIDs are the expensive ones. However, a con-
cern arises whether the anticipated savings of policy im-
plementation may be offset by increased costs of
substitutable drugs and/or medical services. It is also im-
